Synonym
Corrector C-18; Corrector C 18; Corrector C18
IUPAC/Chemical Name
1-(Benzo[d][1,3]dioxol-5-yl)-N-(5-((S)-(2-chlorophenyl)((R)-3-hydroxypyrrolidin-1-yl)methyl)thiazol-2-yl)cyclopropanecarboxamide
InChi Key
OUGLISSDQZYBGK-ZHRRBRCNSA-N
InChi Code
InChI=1S/C25H24ClN3O4S/c26-18-4-2-1-3-17(18)22(29-10-7-16(30)13-29)21-12-27-24(34-21)28-23(31)25(8-9-25)15-5-6-19-20(11-15)33-14-32-19/h1-6,11-12,16,22,30H,7-10,13-14H2,(H,27,28,31)/t16-,22+/m1/s1
SMILES Code
O=C(C1(C2=CC(OCO3)=C3C=C2)CC1)NC4=NC=C([C@H](C5=CC=CC=C5Cl)N6C[C@H](O)CC6)S4
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
497.99
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Chen X, Zhu S, Zhenin M, Xu W, Bose SJ, Wong MP, Leung GPH, Senderowitz H, Chen JH. A defective flexible loop contributes to the processing and gating defects of the predominant cystic fibrosis-causing mutation. FASEB J. 2019 Apr;33(4):5126-5142. doi: 10.1096/fj.201801218RR. Epub 2019 Jan 22. PubMed PMID: 30668920.
2: Zeng M, Szymczak M, Ahuja M, Zheng C, Yin H, Swaim W, Chiorini JA, Bridges RJ, Muallem S. Restoration of CFTR Activity in Ducts Rescues Acinar Cell Function and Reduces Inflammation in Pancreatic and Salivary Glands of Mice. Gastroenterology. 2017 Oct;153(4):1148-1159. doi: 10.1053/j.gastro.2017.06.011. Epub 2017 Jun 19. PubMed PMID: 28634110; PubMed Central PMCID: PMC5623154.
3: Awatade NT, Uliyakina I, Farinha CM, Clarke LA, Mendes K, Solé A, Pastor J, Ramos MM, Amaral MD. Measurements of Functional Responses in Human Primary Lung Cells as a Basis for Personalized Therapy for Cystic Fibrosis. EBioMedicine. 2014 Dec 17;2(2):147-53. doi: 10.1016/j.ebiom.2014.12.005. eCollection 2015. PubMed PMID: 26137539; PubMed Central PMCID: PMC4484512.
4: Velard F, Delion M, Lemaire F, Tabary O, Guillaume C, Le Pimpec Barthès F, Touqui L, Gangloff S, Sermet-Gaudelus I, Jacquot J. Cystic fibrosis bone disease: is the CFTR corrector C18 an option for therapy? Eur Respir J. 2015 Mar;45(3):845-8. doi: 10.1183/09031936.00174014. Epub 2014 Nov 27. PubMed PMID: 25431270.
